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tremity, pitting edema extending to the mid-thigh. No other
abnormalities were found. Urinalysis revealed 4 proteinuria,
numerous hyaline casts, and no hematuria or leukocyturia. A
24-hour urine collection contained 10 g of protein. A fasting
serum chemistry panel showed severe hypoalbuminemia, 2.1
g/dL; hypercholesterolemia, 387 mg/dL; hypertriglyceridemia,
420 mg/dL; mild hyponatremia, 132 mEq/L; and a normal glu-
cose level. Tests for antinuclear antibody, antidouble-stranded
DNA antibody, hepatitis, and HIV serologies, as well as a rapid
plasma reagin (RPR) test were negative. Complement levels
were within the normal range. Light, immunofluorescent, and
electron microscopy of a percutaneous renal biopsy specimen
revealed unequivocal evidence of membranous nephropathy.
CASE PRESENTATION DISCUSSION
A 37-year-old executive was referred by her internist to the
Dr. Nosratola D. Vaziri (Chief, Division of Nephrol-nephrology service at the University of California at Irvine for
ogy and Hypertension; and Professor of Medicine, Physi-evaluation of proteinuria and lower extremity edema. She had
been healthy until 2 months prior to referral when she first ology, and Biophysics, University of California, Irvine,
noticed mild swelling of her ankles in the late afternoon. During California, USA): This patient represents a typical case
the ensuing weeks, the edema steadily increased, extending to of nephrotic syndrome (NS) exhibiting heavy protein-
her legs and subsequently to the lower portion of her thighs.
uria, hypoalbuminemia, sodium retention, and hyperlip-A review of systems was unremarkable except for the recent
idemia. Hyperlipidemia is one of the cardinal manifesta-onset of diminished exercise capacity and lower extremity
edema. The past medical history was negative except for an tions of NS. Nephrotic hyperlipidemia is marked by
appendectomy 17 years ago. Because the patient was adopted elevations of plasma low-density lipoprotein (LDL), very
when she was 2 years old, her family history was unknown. low-density lipoprotein (VLDL), intermediate-density
She is married and has no children. She does not smoke and
lipoprotein (IDL), and lipoprotein(a) [LP(a)] [1–5]. Ne-denies use of illicit drugs or exposure to solvents, heavy metals,
phrotic hyperlipidemia also is frequently accompaniedor industrial or occupational toxins. A thorough annual medical
by a reduced [6] or unchanged [1] HDL concentrationevaluation 6 months ago had been normal. Results from labora-
tory tests at that time all were within normal limits, including and an increased LDL/HDL cholesterol ratio. These ab-
the hemogram, lipid profile, urinalysis, blood urea nitrogen, normalities denote a high risk for cardiovascular disease
creatinine and albumin concentrations, and liver function tests. in patients with chronic NS. In addition, NS significantly
A test for occult blood in the stool was negative. A mammo-
alters the composition of lipoproteins. For instance, thegram and Pap smear were normal.
ratios of cholesterol to triglycerides, free cholesterol toThe current physical examination was notable for mild hy-
pertension (140/90 mm Hg) and marked bilateral, lower ex- cholesterol esters, and phospholipids to proteins are sig-
nificantly increased in all lipoprotein fractions in NS [6].
These alterations are accompanied by impaired clear-
The Nephrology Forum is funded in part by grants from Amgen, ance of VLDL and chylomicrons, and accumulation ofIncorporated; Merck & Co., Incorporated; Dialysis Clinic, Incorpo-
their atherogenic remnants in the plasma [1, 7–11]. Inrated; and Bristol-Myers Squibb Company.
the course of this presentation, I will review the effect
Key words: proteinuria, hyperlipidemia, cholesterol, HMG-CoA re-
of NS on the metabolism of different classes of plasmaductase, LCAT, ACAT, lipoprotein lipase, hepatic lipase, SR-B1,
HDL, LDL, VLDL. lipoproteins and the relevant lipid regulatory enzymes
and receptors. 2003 by the International Society of Nephrology
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LDL and cholesterol metabolism regulate, HMG-CoA reductase, and glucagon counter-
acts insulin’s action [14].Plasma LDL and total cholesterol are markedly ele-
In our initial study of rats with puromycin-induced NSvated in NS. Elevation of plasma LDL in NS is thought
(a popular model of minimal-change disease), we foundto be due to increased LDL synthesis [7] and depressed
a marked up-regulation of HMG-CoA reductase mRNALDL catabolism [1]. In fact, Warwick et al [10, 12] have
and enzymatic activity during the induction phase of pro-demonstrated a significant reduction in the rate of catab-
teinuria and hypercholesterolemia [15]. These changesolism of apolipoprotein B (Apo B), the principal apo-
were followed by a gradual decline in HMG-CoA reductaseprotein constituent of LDL. Most of the earlier studies
mRNA and activity toward baseline values despite persis-of lipid metabolism in NS had focused on characteriza-
tent hypercholesterolemia during the chronic phase of NS.tion of the plasma lipid profile, determination of the
Interestingly, withdrawal of food for 20 hours resulted inrate of clearance of labeled lipoprotein fractions, indirect
a pronounced but transient up-regulation of HMG-CoAmeasurements of lipid biosynthesis, and apoprotein ex-
reductase in rats with chronic nephrosis but had no effectpressions. However, until recently, the molecular bases
in the control rats. These observations suggest that up-of altered cholesterol biosynthesis and catabolism were
regulation of HMG-CoA reductase during the inductionnot known, and the mechanism of impaired LDL clear-
phase, and with food restriction during the chronic phase,ance had not been elucidated. To explore the molecular
contributes to generation and maintenance of hypercho-mechanisms of nephrotic hypercholesterolemia, we car-
lesterolemia in NS [15]. In contrast to the nephrotic ani-ried out a series of studies testing the hypothesis that
mals, rats fed a high-cholesterol, high-saturated fat diet tothe marked rise in serum cholesterol characteristic of
produce an equally severe hypercholesterolemia showedNS must be due either to increased biosynthesis and/or
an appropriate down-regulation of hepatic HMG-CoA re-to decreased cholesterol catabolism. To this end, we first
ductase expression and activity [15]. These observationsexamined the effect of NS on hepatic tissue expression
point to a defective HMG-CoA reductase regulatoryof 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA)
response to hypercholesterolemia in NS.
reductase, the rate-limiting enzyme in cholesterol bio-
In a recent study, we found a marked increase in immu-
synthesis. We then studied expression of hepatic choles- nodetectable HMG-CoA reductase protein abundance
terol 7-hydroxylase (Ch 7-hydroxylase), the rate-limit- in the livers of Imai rats with spontaneous focal glomeru-
ing step in cholesterol catabolism to bile acids. We losclerosis and severe nephrotic proteinuria [16]. This
subsequently examined the hepatic LDL receptor to fur- observation proved that up-regulation of HMG-CoA re-
ther explore the mechanism of hypercholesterolemia and ductase in nephritic syndrome is independent of the
impaired LDL clearance in NS. Finally, we investigated cause of the underlying glomerulopathy. In an attempt to
the expression of the liver-specific enzyme, acylcoenzyme dissect the effect of proteinuria from that of the resultant
A:cholesterol acyltransferase-2 (ACAT-2), which plays hypoalbuminemia, we examined hepatic tissue expres-
a critical role in cholesterol signaling as well as in assem- sion of immunodetectable HMG-CoA reductase in Na-
bly and secretion of Apo B-containing lipoproteins. I gase rats with hereditary analbuminemia. We found a
will briefly describe the functions of these proteins and significant up-regulation of hepatic HMG-CoA reduc-
their alterations in NS. tase in male Nagase rats that exhibited profound hypo-
HMG-CoA reductase is the rate-limiting enzyme in albuminemia and mild hypercholesterolemia (unpublished
the biosynthesis of cholesterol. Hepatic HMG-CoA re- data). Up-regulation of HMG-CoA reductase expression
ductase activity closely correlates with cholesterol bio- in both NS and hereditary analbuminemia, which share
synthesis under a broad range of cholesterol biosynthetic hypoalbuminemia but not proteinuria, indicates the role
rates [13]. Although it is expressed in virtually all tissues, of hypoalbuminemia per se in mediating this change.
it is most abundant in the liver, which plays a central The principal pathway of cholesterol catabolism is its
role in the regulation of plasma cholesterol. Hepatic conversion to bile acids for secretion into the small intes-
HMG-CoA reductase expression and activity are tightly tine and eventual fecal excretion. Ch 7-hydroxylase is
regulated by intracellular free cholesterol (or oxycholes- the first and the rate-limiting step in cholesterol conversion
terols), which can suppress the transcription, translation, to bile acids and, as such, plays a critical role in choles-
and catalytic activity of the enzyme [14]. Similarly, bile terol catabolism. Expression of this unique cytochrome
acids, the main products of cholesterol catabolism, exert P450 enzyme is up-regulated by increased intracellular
a negative feedback on hepatic HMG-CoA reductase at free cholesterol concentration, thyroid hormone, high
the levels of transcription, translation, and enzymatic cholesterol intake, and bile acid depletion. In contrast,
activity. Finally, hepatic expression and activity of this bile acids, glucocorticoids, and starvation down-regulate
enzyme are influenced by diurnal variation and numer- Ch 7-hydroxylase [17]. Given the critical role of Ch
ous hormones. For instance, thyroid hormone, insulin, 7-hydroxylase in cholesterol metabolism, we explored
expression of hepatic Ch 7-hydroxylase in rats withand estrogen up-regulate, whereas glucocorticoids down-
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NS, rats with diet-induced hyperlipidemia, and normal Ch 7-hydroxylase expressions in nephrotic animals
[15, 18].control rats. The study revealed a marked up-regulation
Regulation of HMG-CoA reductase, Ch 7-hydroxy-of Ch 7-hydroxylase mRNA and immunodetectable pro-
lase, and other cholesterol-responsive factors by choles-tein in rats with diet-induced hypercholesterolemia. How-
terol depends on intracellular free cholesterol as opposedever, despite equally severe hypercholesterolemia, neph-
to cholesterol esters, which constitute the bulk of therotic rats showed no rise in either Ch 7-hydroxylase
cellular cholesterol pool. Given the importance of cellu-mRNA or protein abundance [16, 18]. In a subsequent
lar free-cholesterol concentration and the cholesterol es-study, we found that bile secretion rate was markedly
terification system in cholesterol metabolism, we exam-elevated in rats with diet-induced hypercholesterolemia
ined gene expression, protein abundance, and enzymaticbut was virtually unchanged in the nephrotic rats, thus
activity of the liver-specific enzyme ACAT-2, which isdemonstrating the inability of nephrotic animals to in-
responsible for esterification of cholesterol in the livercrease bile secretion rate in response to severe hypercho-
[16, 21].lesterolemia [19].
Primarily localized in the endoplasmic reticulum, ACATTo discern the reason for the disparity in hepatic
catalyzes intracellular esterification of cholesterol andHMG-CoA reductase and Ch 7-hydroxylase expression
formation of cholesterol esters in nearly all mammalianbetween the nephrotic and diet-induced hypercholester-
cells. Recently, two distinct isoforms of ACAT, ACAT-1olemias, we measured intracellular cholesterol concen-
and ACAT-2, have been identified in the hepatocytestration, which plays a major role in the regulation of these
of humans and animals [22–24]. ACAT-1 is ubiquitouslyenzymes. The study showed a 16-fold increase in hepatic
expressed in all tissues, whereas ACAT-2 is primarilytissue cholesterol content in rats with diet-induced hy-
expressed in the liver and intestine. Esterification of cho-percholesterolemia, but no increase in the nephrotic ani-
lesterol by ACAT limits its solubility in the cell mem-mals despite equally severe hypercholesterolemia [15, 18].
brane lipids and promotes accumulation of cholesterolThese observations point to the lack of rise in hepatocel-
esters in the fat droplets. By modulating intracellular freelular cholesterol content as an underlying mechanism
cholesterol concentration, ACAT regulates cholesterolfor the observed dysregulation of HMG-CoA reductase
signaling pathways [25]. In addition, ACAT-mediatedand Ch 7-hydroxylase in NS. To elucidate the mecha-
esterification of cholesterol contributes to production,nism of the observed discordance in plasma and hepato-
packaging, and release of VLDL by the liver [26]. Finally,cyte cholesterol levels, we next explored the effect of
ACAT contributes to cholesterol ester accumulation inNS on LDL receptor expression.
macrophages and vascular tissue, hence, foam cell forma-Hepatic cholesterol uptake represents the primary path-
tion and atherosclerosis [27].
way of cholesterol clearance from the circulation. We
Free cholesterol regulates HMG-CoA reductase and
therefore considered that discordance between plasma Ch 7-hydroxylase, and ACAT modulates cellular free
and hepatocyte cholesterol concentrations and the resul- cholesterol level, so we hypothesized that dysregulation
tant dysregulations of HMG-CoA reductase [15, 16] and of lipid metabolism in NS in part reflects a possible up-
Ch 7-hydroxylase [16, 18] in NS might be partly due regulation of hepatic ACAT activity. Therefore we deter-
to impaired hepatic cholesterol uptake. As the LDL re- mined the mRNA abundance, immunodetectable protein,
ceptor provides the predominant pathway for plasma and enzymatic activity of the liver-specific ACAT-2 in rats
cholesterol clearance, we hypothesized that NS results with chronic NS caused by either puromycin or spontane-
in acquired LDL receptor deficiency. To test this hypoth- ous focal glomerulosclerosis and compared the results
esis, we determined LDL receptor mRNA and protein with those obtained in normal control rats [16, 21]. To
abundance and gene transcription rate in the livers of dissect the effect of proteinuria from that of hypoalbumi-
nephrotic and control rats [16, 20]. The results showed nemia, we included a group of Nagase rats with heredi-
severe reduction of hepatic LDL receptor protein abun- tary analbuminemia in the study. The nephrotic animals
dance in the nephrotic animals despite normal LDL re- exhibited a 3- to 4-fold increase in liver tissue ACAT-2
ceptor mRNA abundance and gene transcription rate. mRNA and protein abundance as well as enzymatic ac-
The latter findings point to inefficient translation and/or tivity. The increase was accompanied by a significant
increased LDL receptor protein turnover as a cause of reduction of hepatic tissue free–cholesterol concentra-
LDL receptor deficiency in NS. Given the critical role tion, which provided functional evidence for excess
of LDL receptor, acquired LDL receptor deficiency must ACAT-2 activity in the nephrotic liver. In contrast, de-
contribute to hypercholesterolemia, elevation of plasma spite extreme hypoalbuminemia, rats with hereditary an-
LDL, impaired LDL clearance [10], and inappropriately albuminemia showed only a mild elevation of hepatic
low hepatocellular cholesterol in NS. The reduction in ACAT-2 mRNA, protein, and enzymatic activity. He-
hepatocellular cholesterol concentration can, in part, ac- patic ACAT-2 protein and activity strongly correlated
with plasma lipid concentrations and urinary proteincount for dysregulation of HMG-CoA reductase and
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excretion. The study therefore demonstrated a marked Apo A-II (20% of HDL protein), which are produced
by the liver and intestine. (The remaining 10% consistup-regulation of hepatic ACAT-2 and its possible contri-
bution to the associated dyslipidemia in NS. The study of Apo A-IV, Apo C, and Apo E.) These apoproteins
are secreted with VLDL and chylomicrons. After reachingfurther showed that elevation of hepatic ACAT-2 in NS
is primarily due to proteinuria as opposed to hypoalbu- the extracellular space, Apo A-I and Apo A-II disassoci-
ate from the original particles as phospholipid complexesminemia [21]. The observed overexpression of hepatic
ACAT-2 can, in part, contribute to dysregulation of and coalesce to form the nascent HDL. Subsequently,
nascent HDL particles incorporate Apo C-phospholipidHMG-CoA reductase and Ch 7-hydroxylase [28] by
lowering intracellular free-cholesterol concentration while and Apo E-phospholipid complexes, which are either
derived from lipolysis of VLDL and chylomicrons bysimultaneously generating abundant supplies of choles-
terol esters for incorporation into Apo B-containing lipo- lipoprotein lipase or are directly secreted by the liver.
These events lead to formation of small cholesterol-poorproteins.
To determine the effect of NS on the intestinal trans- HDL-3 particles. As reviewed by Genest et al [29], re-
trieval of surplus cholesterol by the small cholesterol-port of cholesterol, we measured the rate of absorption
of micellar preparations of cholesterol in nephrotic, diet- poor discoid HDL particle begins with its attachment to
the cell surface via HDL-binding protein, which has beeninduced hypercholesterolemic, and in control rats. The
results showed no significant difference in the rates of shown to be identical to vigilin. The binding of HDL to
its binding protein leads to mobilization of intracellularcholesterol absorption among the study groups. Thus,
neither nephrotic hyperlipidemia nor diet-induced hyper- cholesterol pools and translocation of free cholesterol
via the Golgi apparatus to the caveolae and ultimatelylipidemia affects intestinal absorption of cholesterol [19].
In sum, NS is associated with a relative elevation of to the plasma membrane. Accumulation of free choles-
terol in the plasma membrane generates a concentrationhepatic HMG-CoA reductase, the rate-limiting enzyme
in cholesterol biosynthesis, and with a relative reduction gradient favoring its diffusion to the surface of the HDL
particle. Free cholesterol reaching the surface of HDL isof Ch 7-hydroxylase, the rate-limiting enzyme in choles-
terol catabolism. These alterations are accompanied by, immediately esterified by the enzyme lecithin:cholesterol
acyltransferase (LCAT) in the presence of its cofactorand are at least in part due to, LDL receptor deficiency,
which limits hepatic cholesterol uptake, and up-regulation Apo A-I to form cholesterol ester. Because of its intense
hydrophobicity, cholesterol ester formed on the surfaceof hepatic ACAT-2, which lowers hepatocyte free-choles-
terol concentration. These molecular events can account sinks into the core of the HDL particle, thus sustaining
the favorable gradient for maximal cholesterol uptakefor the induction and maintenance of nephrotic hyper-
cholesterolemia, impaired LDL clearance, and choles- by the maturing HDL. Once fully loaded, the cholesterol
ester–rich HDL particle dissociates from the HDL bind-terol enrichment of VLDL and newly synthesized LDL
particles. ing protein and returns to the circulation for transport
to the liver. In the circulation, the cholesterol ester–rich
HDL metabolism HDL-2 particle donates part of its cholesterol ester cargo
to VLDL remnants (IDL) in exchange for triglycerides.The primary function of HDL is retrieval of surplus
cholesterol from extrahepatic tissues for disposal in the This process is facilitated by plasma cholesterol ester
transfer protein (CETP), which is present in humans butliver. Cholesterol ester delivery by HDL to the liver can
occur either directly via receptor-mediated processes or absent in rats. In addition, HDL acquires Apo C and
Apo E from VLDL and chylomicron remnants for subse-indirectly via transfer of cholesterol esters to Apo B100-
containing particles and their uptake by LDL receptor or quent donation to the nascent VLDL and chylomicrons.
These events lead to further reduction of triglycerideby LDL-receptor-related protein (LRP). HDL-mediated
cholesterol retrieval, commonly known as reverse choles- content of the VLDL remnants, thus contributing to their
eventual conversion to LDL or hepatic removal by eitherterol transport, is essential for cellular cholesterol homeo-
stasis and protection against atherosclerotic cardiovascu- LDL receptors or LRP-mediated endocytosis. Extrac-
tion of Apo C proteins from the remnant particles bylar disease. Other functions of HDL include participation
in the shuttling of Apo C and Apo E proteins between HDL is necessary for the uptake of remnants by the liver,
as the receptor binding is inhibited by Apo C proteins.nascent triglyceride-rich lipoproteins and their remnants,
transport of clusterin and paraoxonase, delivery of cho- Moreover, donation of Apo C and Apo E to the nascent
VLDL and chylomicrons by HDL is critical for theirlesterol to steroidogenic glands (for example, adrenal
and gonads), adsorption of bacterial endotoxins, inhibi- subsequent lipolysis by lipoprotein lipase (LPL). This is
because Apo E is necessary for their binding to thetion of platelet aggregation (via regulation of Cox-2), and
modulation of cytokine-mediated endothelial adhesion endothelial surface and Apo C-II is necessary for activa-
tion of LPL. Finally, the lipid-loaded HDL particle bindsmolecule expression [29]. The main apoprotein constit-
uents of HDL are Apo A-I (70% of HDL protein) and to the newly discovered HDL receptor, which serves as
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by urinary losses of proteins of intermediate molecular
weight; the molecular mass of LCAT (63 kD) is very
close to that of albumin. In contrast to the nephrotic
animals, the Nagase rats with hereditary analbuminemia
showed normal LCAT mRNA abundance in the liver
and normal plasma and urine LCAT activity. These ob-
servations suggested that LCAT deficiency in NS is due
to proteinuria, not hypoalbuminemia.
In the presence of LCAT deficiency, accumulation of
unprocessed free cholesterol on the surface of HDL lim-
its the gradient-driven cholesterol uptake by HDL. This
limitation leads to a rise in cellular cholesterol and im-
paired maturation of cholesterol-poor HDL-3 to choles-
Fig. 1. Reverse cholesterol transport from extrahepatic tissues to the terol ester–rich HDL-2 [33, 34]. In addition to trans-liver by high-density lipoprotein (HDL). Abbreviations are: HDL r,
porting the surplus cholesterol to the liver, HDL shuttlesHDL receptor; LCAT, lecithin:cholesterol acyltransferase.
Apo C-II and Apo E between nascent VLDL and chy-
lomicrons and their remnants [35]. Among HDL species,
HDL-2 is the most efficient donor of Apo C-II and
a docking platform for the HDL-2 particle [30]. The Apo E. Therefore, an LCAT deficiency–induced reduc-
reversible binding to the receptor facilitates unloading of tion of HDL-2 reduces Apo C-II (cofactor of lipoprotein
the HDL’s cholesterol ester content into the hepatocyte. lipase) and Apo E (ligand for endothelial heparan sul-
This transfer of the cholesterol ester is accompanied by fate) in VLDL and chylomicrons, which, in turn, can
extraction of the fatty acids derived from hydrolysis of depress lipolysis of VLDL and chylomicrons and pro-
triglyceride content of HDL by hepatic triglyceride li- mote hypertriglyceridemia. Unlike rats, humans possess
pase. The lipid-depleted HDL-3 particle disassociates CETP, which catalyzes the exchange of triglycerides in
from the HDL receptor and returns to the circulation, VLDL remnants for cholesterol ester in HDL. There-
where it serves as a recycling shuttle (Fig. 1). In addition fore, reduction in the cholesterol ester content of HDL,
to the HDL receptor–mediated pathway, which results occasioned by LCAT deficiency in humans, can limit
in the exclusive removal of HDL lipid contents, some maturation of VLDL remnants and lead to generation
HDL particles containing Apo E can be removed in their of abnormal particles with a high-triglyceride content.
entirety by hepatic LRP or LDL receptor. Plasma HDL Thus, the severe LCAT deficiency shown in our study
concentration is frequently reduced [6] or unchanged [32] can contribute to the reported abnormalities of HDL
[1] and LDL/HDL ratio is markedly elevated in NS. In maturation and metabolism [31], as well as to impaired
addition, maturation of lipid-poor HDL-3 to cardiopro- clearance and abnormal composition of VLDL and chy-
tective cholesterol-rich HDL-2 is impaired and leads to lomicrons and their remnants in NS [1, 7–9, 36], com-
a significant elevation of HDL-3 and a marked reduction pounding the effects of lipoprotein lipase, hepatic triglyc-
in HDL-2 in NS [31]. eride lipase, and VLDL receptor deficiencies [37–39].
Given the critical role of LCAT in maturation of cho- Apo A-I (molecular mass, 28 kD) is the main structural
lesterol-poor HDL-3 to cholesterol ester–rich cardiopro- component of HDL, the obligate cofactor for LCAT,
tective HDL-2, we hypothesized that the elevation of and the likely ligand for the HDL binding protein (vig-
HDL-3/HDL-2 ratio, as well as the relative reduction of ilin) and HDL receptor (SR-B1). Synthesized by the
HDL cholesterol to total cholesterol in NS, might be liver and intestine, it is primarily catabolized by liver,
indicative of LCAT deficiency. To test this hypothesis, kidney, skin, and other tissues. Hepatic Apo A-I mRNA
we recently studied expression of LCAT mRNA in the is increased, its fractional catabolic rate is reduced, and
liver and enzymatic activity and protein concentration despite its urinary losses, plasma Apo A-I concentration
of LCAT in the plasma and urine of nephrotic rats. We is elevated in nephrotic rats [40, 41]. In contrast to rats,
compared the results with those obtained in Nagase rats fractional catabolism of Apo A-I is often elevated in
with hereditary analbuminemia and normal control ani- nephrotic humans [42]. The observed disparity appears
mals [16, 32]. The study revealed a marked reduction of to be due to the absence in the rat [43] and upregulation
plasma LCAT and heavy urinary losses of the enzyme in in nephrotic humans [44] of CETP, which catalyzes trans-
the nephrotic group. Plasma LCAT activity was inversely fer of cholesterol esters from HDL-2 to VLDL remnants.
related to its urinary excretion. However, LCAT mRNA This process favors formation of HDL-3; HDL-3’s affin-
abundance in the liver tissue was not altered by NS. ity for Apo A-I is less than that of HDL-2 [45]. Therefore,
These findings suggested that the urinary losses contrib- an increased level of cholesterol-ester-poor HDL-3 occa-
sioned by elevated CETP [44], and reduced LCAT [32]ute to LCAT deficiency in NS, a condition characterized
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can contribute to elevation of unincorporated Apo A-I, ated uptake of surplus cholesterol from extrahepatic
tissues. This limitation can contribute to the reportedwhich, owing to its small size, is susceptible to urinary
excretion and catabolism in the kidney [41]. abnormalities of HDL, VLDL, chylomicrons, and their
remnants in NS. Impaired HDL-mediated cholesterolAs I said earlier, HDL plays an important role in the
reverse transport of cholesterol from the extrahepatic uptake from the extrahepatic tissues is compounded by
marked reduction of the hepatic HDL receptor, whichtissues to the liver, as well as delivery of cholesterol esters
to nonplacental steroidogenic tissues (gonads and adre- can limit HDL-mediated cholesterol (and triglyceride)
disposal in the liver. These events work in concert tonal glands). Prior to discovery of the HDL receptor, the
mechanism of cholesterol uptake from HDL by liver limit reverse cholesterol transport and hence cardiovas-
cular, and perhaps renoprotective, actions of HDL. In-and the steroidogenic glands was unknown. The HDL
receptor, originally identified by Acton and colleagues as deed, they probably contribute to cardiovascular compli-
cations in chronic nephrosis.an SR-B1 molcule, is a cell membrane-associated protein,
which is expressed in the liver, adrenal glands, testes,
Triglyceride-rich lipoprotein metabolismand ovaries and which has a high affinity for HDL. Cells
transfected with the HDL receptor gene exhibit a strong The critical role of lipids in energy metabolism is evi-
denced by the fact that as much as 80% of energy pro-saturable binding affinity for HDL. Binding of HDL to
its receptors on the transfected cells removes its lipid duced in the body passes through some lipid intermediary.
Triglyceride-rich lipoproteins, which consist of chylo-contents without uptake or degradation of the HDL apo-
protein constituents [30]. Reversible binding of HDL to microns, VLDL, and their remnants, are the primary
vehicles for transport of fatty acids (as triglycerides)the HDL receptor on the surface of the hepatocyte un-
loads cholesterol esters from the core of HDL into the among the sites of absorption, production, storage, and
consumption. In addition, albumin binds and transportshepatocyte. In addition, binding to the receptor facilitates
lipolysis of triglycerides in the HDL by hepatic triglycer- free fatty acids and lysolecithins.
Chylomicrons serve as the vehicle for transport ofide lipase and removal of fatty acids by the liver. Thus,
unlike the LDL receptor, the HDL receptor serves as a dietary lipids. Nascent chylomicrons are produced in the
enterocytes from fatty droplets containing triglycerides,docking receptor that allows HDL to operate as a recy-
cling shuttle for cholesterol transport from the extrahe- phospholipids, and cholesterol esters supplemented with
an array of apoproteins including Apo B-48, Apo A-I,patic tissues to the liver and steroidogenic glands. Nota-
bly, hepatic removal and catabolism of Apo A-I involve Apo A-II, and Apo A-IV. After being released in the
circulation via the lymphatic system, nascent chylo-a different and as-yet-unidentified pathway with niacin-
responsive and niacin-unresponsive components [46]. microns acquire free cholesterol, Apo C, and Apo E
from HDL in exchange for Apo A-I, Apo A-II, andTo discern the possible effect of NS on hepatic HDL
receptor expression, we studied HDL receptor mRNA phospholipid. Acquisition of Apo C and Apo E from
HDL is essential for the subsequent lipolysis of chylomi-and immunodetectable HDL receptor protein abun-
dance in rats with chronic NS [47]. The nephrotic animals crons by lipoprotein lipase, which requires Apo C-II for
enzymatic activity and Apo E for particle binding to theshowed marked down-regulation of hepatic HDL recep-
tor protein expression that was accompanied by a normal endothelial surface (Fig. 2).
Very-low-density lipoprotein is the vehicle for trans-HDL receptor mRNA abundance. Thus, NS appears to
affect the hepatic HDL receptor at the level of protein port of endogenous lipids. Nascent VLDL is produced
in the hepatocyte from fusion of partially lipidated, newlyin a manner virtually identical to that seen with LDL
receptor expression [20]. Combined down-regulation of synthesized Apo B-100 with a triglyceride-rich particle
and subsequent addition of Apo E, Apo A-I, and Apothe hepatic HDL receptor and LDL receptor, which
represent the two major pathways of plasma cholesterol A-II. After release into the circulation, nascent VLDL
acquires Apo C and Apo E from HDL in exchange forclearance, can play a central role in the pathogenesis of
nephrotic hypercholesterolemia and the associated dys- Apo A-I, Apo A-II, and additional phospholipid. Again,
acquisition of additional Apo E is needed for properregulation of HMG-CoA reductase and Ch 7-hydroxy-
lase expressions [15, 18]. As I noted earlier, in addition to binding, while acquisition of Apo C-II is necessary for
optimal lipolysis of VLDL by lipoprotein lipase. Fattyaccommodating the removal of cholesterol esters, HDL
binding to HDL receptor facilitates hydrolysis of HDL acids used for incorporation into VLDL in the liver are
derived from de novo synthesis from surplus carbohy-triglycerides by hepatic triglyceride lipase, which is also
severely depressed in NS [38]. Thus, combined HDL drates, plasma albumin-bound fatty acid pool and he-
patic lipase-mediated lipolysis or receptor-mediated up-receptor and hepatic triglyceride lipase deficiencies can
severely affect HDL-dependent lipid transport in NS. take of IDL, and chylomicron remnants and HDL.
Triglyceride-rich lipoproteins deliver fatty acids asIn short, proteinuria produces urinary losses of LCAT
and severe LCAT deficiency, which limit the HDL-medi- triglycerides to various tissues for energy production
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Fig. 2. Formation and metabolism of chylo-
microns (CM). Abbreviations are: LPL, lipo-
protein lipase; LRP, low-density lipoprotein
(LDL)-receptor-related protein, also known
as remnant receptor; HDL, high-density lipo-
protein; Apo C & E, apolipoprotein C and E.
(skeletal muscle and myocardium) or energy storage (ad- of lipids and lipoproteins can contribute to the nephrotic
hyperlipidemia [48], impaired clearance of chylomicronsipose tissue). Delivery of fatty acids to these tissues in-
volves hydrolysis of triglyceride by lipoprotein lipase [49, 50] and VLDL [9, 49] has emerged as the dominant
factor. Impaired VLDL and chylomicron clearance inleading to release of two fatty acids, followed by removal
of the third fatty acid, which involves a separate monog- NS was originally attributed to proteinuria, not hypo-
albuminemia [49]. Recently, however, Shearer et al [50]lyceridase system. Two thirds of the fatty acids released
from VLDL and chylomicrons diffuse into the adjacent have demonstrated that both proteinuria and hypo-
albuminemia can separately contribute to impaired lipo-myocytes or adipocytes for energy production or storage,
respectively. However, the remaining free fatty acids en- protein catabolism.
Lipoprotein lipase (LPL) is the rate-limiting step inter the plasma pool bound to albumin or lipoproteins for
transport to distant sites, mainly the liver. Lipoprotein lipolysis of VLDL and chylomicrons [51]. This glycopro-
tein enzyme is a member of the lipase family, which alsolipase-mediated lipolysis causes an approximately 70%
reduction in triglyceride contents of chylomicrons and includes hepatic triglyceride lipase and pancreatic lipase.
Heavily expressed in adipose tissue, skeletal muscle,VLDL under normal conditions. This reduction signifi-
cantly decreases the particle diameter coupled with par- myocardium, and several other tissues, LPL is produced
as an inactive enzyme that requires sequential glycation,tial transfer of phospholipid/free cholesterol monolayer,
substantial transfer of Apo E, and total transfer of Apo C glucose trimming, and cleavage of a 27 amino acid pep-
tide to become active. The LPL is then stored in theand Apo A from the shrinking chylomicrons or VLDL
to the adjacent HDL. The chylomicron remnants formed Golgi vesicles and directed for either intracellular degra-
dation or secretion to the cell surface [52]. The secretedin this manner are endocytosed by hepatocytes via LRP.
In the hepatocyte, part of the triglycerides released from LPL binds to heparan sulfate proteoglycans on the cell
surface and eventually translocates to the lumen of thechylomicron remnants is returned to the circulation via
newly synthesized VLDL. In the circulation, the VLDL adjacent capillaries, where it attaches to the heparan
sulfate on the endothelial cells. Only the endothelial-remnants (IDL) donate part of their remaining triglycer-
ides to the nearby HDL in exchange for cholesterol es- bound pool of LPL is relevant to lipolysis of VLDL and
chylomicrons. Since soluble heparin can displace andters with the aid of CETP. Thereafter, most of the IDL
undergoes further lipolysis by hepatic triglyceride lipase release LPL from the binding sites, measurement of
plasma post heparin lipolytic activity or heparin releas-and becomes LDL, which normally consists exclusively
of Apo B-100 with a core of cholesterol ester and negligi- able LPL can be used to investigate LPL activity in
humans and animals. Several in vivo studies had demon-ble amounts of triglycerides (major pathway). The re-
maining IDLs are removed by the liver via either LDL strated marked reduction of heparin-releasable LPL in
nephrotic animals and humans [8, 9, 11, 36, 49, 53, 54].receptor or LRP (minor pathway) (Fig. 3).
Plasma concentrations of triglycerides, VLDL, and However, the effect of NS on gene expression and pro-
tein abundance of LPL in the relevant tissues such asIDL remnants are markedly elevated, triglyceride con-
tent of Apo B–containing lipoproteins is increased, and skeletal muscle, myocardium, and adipose tissue was not
known. Our studies showed significant reductions of hep-clearance of VLDL and chylomicrons is significantly im-
paired in NS [1, 7, 9–11]. Although increased production arin-releasable, nonreleasable (intracellular), and total
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Fig. 3. Formation and metabolism of very
low-density lipoprotein (VLDL), intermedi-
ate-density lipoprotein (IDL), and low-den-
sity lipoprotein (LDL). Abbreviations are:
HTL, hepatic triglyceride lipase; LDL r, LDL
receptor; VLDL r, VLDL receptor; LPL, lipo-
protein lipase; LRP, LDL-receptor-related
protein, also known as remnant receptor; TG,
triglyceride; CE, cholesterol ester.
LPL activities in the myocardium and adipose tissues critical role in maturation of IDL to LDL and in triglycer-
ide unloading of HDL-2 in the liver. Plasma IDL isand of total LPL activity in the skeletal muscle of ne-
phrotic rats [37]. These reductions were accompanied by markedly elevated, and composition of HDL is abnormal
in NS [1, 5, 6, 8, 9, 11, 58, 59]; both of these alterationsmarked reductions of LPL protein abundance in all tested
tissues and of LPL mRNA in the myocardium. However, point to depressed hepatic lipase activity. In fact, in vitro
perfusion of livers from rats with puromycin-induced NSdespite significant reductions in LPL activity and protein
abundance, LPL mRNA abundance in skeletal muscle yields 50% lower heparin-releasable lipase activity as
compared with control rats [9]. We demonstrated thatand adipose tissue of the nephrotic rats was unchanged,
reflecting post-translational regulation. In earlier studies, the reduction in hepatic lipase activity in NS is due to
severe down-regulation of hepatic lipase gene expressionwe had shown that by increasing the left ventricular work-
load, hypertension leads to marked up-regulation of LPL [38]. In addition to its role in metabolism of IDL, hepatic
lipase plays a major role in the lipolysis of triglyceridesexpression in the myocardium [55]. Because NS is fre-
quently accompanied by hypertension, coexistent hyper- in HDL-2, which depends on its binding to hepatic HDL
receptor. Therefore, the combination of HDL receptortension can modify the effect of NS on cardiac LPL expres-
sion. The down-regulation of LPL protein abundance and deficiency [47] and hepatic lipase deficiency [38] can se-
verely affect HDL metabolism in NS.enzymatic activity found in puromycin-induced NS was
recently confirmed by our group in nephrotic rats with The VLDL receptor is a newly recognized member of
the LDL receptor family, which binds and internalizesspontaneous focal glomerulosclerosis [56].
Our studies thus demonstrated marked down-regula- VLDL but not LDL. Tissue distribution of VLDL recep-
tor (skeletal muscle, myocardium, and adipose tissue) istion of LPL in skeletal muscle, myocardium, and adipose
tissue, the principal sites of consumption and storage of similar to that of LPL [60–62]. In addition to their shared
tissue distribution, VLDL receptor and LPL appear tofatty acids. The obvious implication of LPL deficiency
relates to its role in the pathogenesis of hyperlipidemia be functionally interdependent [63]. For instance, LPL
facilitates binding of VLDL particles to VLDL receptorand the associated risk of cardiovascular disease. The
less obvious consequence of severe LPL deficiency is its by forming a bridge between heparan sulfate proteogly-
can and VLDL. Nephrotic syndrome is associated withimpact on energy metabolism in skeletal and cardiac
muscles, which draw much of their energy requirements impaired clearance and elevated plasma concentration
of VLDL, which might reflect possible VLDL receptorfrom fatty acids derived from circulating VLDL via LPL
and possibly VLDL receptor. This phenomenon can po- deficiency. Therefore, we studied VLDL receptor mRNA
and protein abundance in skeletal muscle and myocar-tentially contribute to diminished exercise capacity and
easy fatigability, frequently seen in nephrotic patients. dium of nephrotic and control rats and found a marked
reduction of VLDL receptor protein in both tissues inHepatic lipase is another member of the lipase family
that has considerable structural homology with LPL [57]. the nephrotic animals. This decrease was coupled with
a parallel reduction in VLDL receptor mRNA in theHowever, hepatic lipase is distinct from LPL in its tissue
distribution, substrate specificity (IDL and HDL), and cardiac but not skeletal muscle [39]. In a more recent
study, we found a severe progressive reduction of VLDLindependence from Apo C-II. Hepatic lipase plays a
Nephrology Forum: Molecular mechanisms of lipid disorders in NS1972
receptor in the skeletal muscle and adipose tissue of to an LDL-like particle via a disulfide bond. Elevation
of plasma LP(a) constitutes an independent risk factornephrotic rats with spontaneous focal glomerulosclerosis
and severe hyperlipidemia [56]. Given the functional for atherosclerotic cardiovascular disease and vascular
thrombosis [65]. Structural analysis of Apo(a) has re-interdependence of VLDL receptor and LPL, their se-
vere combined deficiency might play a role in the patho- vealed a high degree of homology with plasminogen [66].
The Apo(a) molecule consists of variable numbers (12genesis of the associated hypertriglyceridemia and im-
paired catabolism of triglyceride-rich lipoproteins. to 51) of kringle IV-like repeats, a single kringle V copy,
and an inactive protease-like segment. The wide varia-Does defective VLDL binding play a role in NS? In
an in vitro study, Furukawa et al [64] found that LPL- tion in the number of kringle IV repeats is responsible
for the extreme size polymorphism of this protein andmediated lipolysis is significantly lower with VLDL prep-
arations from nephrotic rats as compared to the VLDL the wide range of plasma LP(a) concentration (more
than 1000-fold) among the general population [67]. Forobtained from normal rats. They further showed that
the defective LPL-mediated lipolysis of the nephrotic this reason, plasma LP(a) levels are often genetically
determined in the general population. Apo(a) is synthe-VLDL can be corrected by the addition of normal rat
HDL. More recently, Shearer et al [50] demonstrated sized by the liver and is partially removed by the kidney.
Plasma LP(a) increases independently of the geneticallythat binding of VLDL from nephrotic rats to cultured
rat aorta endothelial cells is markedly reduced, while determined Apo(a) isoform in patients with NS [68–70].
De Sain-van der Velden et al [71] determined fractionalbinding of VLDL from Nagase rats with hereditary anal-
buminemia is increased. They further showed that defec- catabolic and synthesis rates of LP(a) in a group of 5
nephrotic and 5 normal control individuals. The meantive binding of nephrotic VLDL can be reversed by pre-
incubation of nephrotic VLDL with HDL from either plasma LP(a) concentration in the nephrotic group was
approximately threefold greater than that of the controlnormal or Nagase rats but not with the nephrotic HDL.
Likewise, infusion of normal HDL improved chylo- group. This was accompanied by an increased absolute
micron clearance in nephrotic rats. These observations rate of synthesis but a normal fractional catabolic rate
pointed to an intrinsic defect of triglyceride-rich lipopro- of LP(a), and suggested increased synthesis as the cause
teins in nephrotic animals, which was linked to an abnor- of elevated plasma LP(a) in NS.
mality in nephrotic HDL. Analysis of apoprotein-lipid Owing to its homology with plasminogen, Apo(a) in-
ratios of VLDL and HDL revealed a significant reduc- terferes with plasminogen-mediated fibrinolysis. Conse-
tion in the Apo B-to-triglyceride ratio in nephrotic quently, a high plasma LP(a) concentration produces a
VLDL and a marked reduction in the Apo E-to-Apo prothrombotic diathesis by promoting an imbalance be-
A-I ratio in the nephrotic HDL. A similar reduction in tween coagulation and fibrinolytic systems. This conse-
the Apo E-to-Apo A-I ratio was reported in HDL from quence is of particular interest because NS results in urinary
salt-sensitive Dahl rats with NS [54]. Because HDL is a losses and deficiency of antithrombin III [72]; marked ele-
source of Apo E and Apo C for the nascent VLDL, and vations of plasma factor VIII, von Willebrand factor, factor
these apoproteins are required for activation and binding XIII, fibrinogen, and fibronectin; and increased platelet
to LPL, Shearer et al suggested that Apo E depletion reactivity [73, 74]. The constellation of these abnormali-
of nephrotic HDL can contribute to impaired lipolysis ties creates a profound hypercoagulable state marked by
of triglyceride-rich lipoproteins by LPL [50]. Similarly, a high incidence of thromboembolic events [74, 75].
a relative reduction of Apo E, which is a ligand for the
VLDL receptor, can interfere with its efficient binding
CONCLUSIONand clearance by VLDL receptor [50]. Lipoprotein lipase
The induction of hypercholesterolemia during thedeficiency appears to be partly responsible for dimin-
early phase of NS is accompanied by, and primarily re-ished Apo E content of HDL because LPL-mediated
lated to, up-regulation of HMG-CoA reductase. Mainte-lipolysis of VLDL is required for the transfer of Apo C
nance of hypercholesterolemia in the chronic phase of NSand Apo E from VLDL remnants to HDL. It is therefore
is supported by the up-regulation of hepatic ACAT andintuitive that insufficient lipolysis of VLDL due to LPL
down-regulations of LDL receptor and HDL receptor.deficiency can limit the ability of HDL to maintain ade-
Urinary losses of LCAT result in severe LCAT deficiency,quate supplies of Apo E. This viewpoint is supported by
which impairs HDL-mediated cholesterol uptake from thestudies by Garber et al [9], who showed a marked in-
extrahepatic tissues in NS. This impairment is accompaniedcrease in Apo E content of HDL following incubation
by down-regulation of hepatic HDL receptor (SR-B1),of nephrotic serum with purified LPL in vitro.
which limits HDL-mediated cholesterol and triglyceride
Lipoprotein(a) disposal in the liver. These events lead to profound dys-
regulation of HDL metabolism and undoubtedly limit theLipoprotein(a) [LP(a)] is formed from the covalent
binding of a protein known as apolipoprotein(a) [Apo(a)] cardiovascular, and perhaps renoprotective, functions of
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HDL. Nephrotic syndrome results in severe down-regu- Dr. Madias: For a number of other enzymes involved
in the metabolism of cholesterol or lipoproteins, youlations of LPL, VLDL receptor, and hepatic triglyceride
suggested that the changes in their activity observed inlipase as well as impairment of HDL-mediated shuttling
the NS are triggered by proteinuria rather than by hypo-of Apo E and Apo C-II between the nascent and remnant
albuminemia. Could you speculate on which consequencesVLDL and chylomicrons. These events are largely re-
of proteinuria might be responsible for such changes?sponsible for profound abnormalities in the metabolism
Dr. Vaziri: Thank you for this intriguing question.of trygliceride-rich lipoproteins in NS. Finally, increased
Once again, the precise mechanisms by which protein-Apo(a) biosynthesis elevates the plasma LP(a) concen-
uria leads to dysregulation of various lipid-regulatorytration and can compound numerous other risk factors
enzymes and receptors is not clear, but we can examine
for cardiovascular disease and thromboembolism in NS. several possibilities. The most popular assumption is the
potential loss in the urine (hence, deficiency) of an unde-
fined lipid regulatory protein that leads to a cascade ofQUESTIONS AND ANSWERS
events culminating in dysregulation of the given enzymes,
Dr. Nicolaos E. Madias (Executive Academic Dean, receptors, and apoproteins. In this regard, our recent
Tufts University School of Medicine, Boston, Massachu- demonstration of heavy urinary losses of LCAT and the
setts): You indicated that the HMG-CoA reductase mes- resultant LCAT deficiency in nephrotic rats [32] lends
sage and abundance increase in the NS as a consequence support to this supposition. For instance, depressed HDL-
mediated, reverse cholesterol transport caused by LCAT-of hypoalbuminemia. How much do we know about the
deficiency can potentially contribute to altered hepatictranscriptional regulation of the HMG-CoA reductase
cholesterol biosynthesis and catabolism by limiting cho-gene? Are there plausible mechanisms for hypoalbumi-
lesterol uptake from extrahepatic tissues. Moreover, asnemia or its consequences to affect such transcription?
I said earlier, by impairing HDL maturation, LCAT de-Dr. Vaziri: A number of factors regulate hepatic
ficiency can compromise VLDL and chylomicron metab-HMG-CoA reductase, not only at the level of transcrip-
olism by limiting HDL-mediated shuttling of Apo C andtion, but also at the level of translation and enzymatic
Apo E between their nascent and remnant forms.activity. These factors include intracellular free choles-
Dr. John T. Harrington (Dean, Tufts Universityterol and bile acid concentrations, as well as several
School of Medicine): My first question concerns the de-
hormones such as thyroid hormone, glucocorticoids, and creased energy metabolism in NS. I’m not sure I under-
gonadal hormones. Reduction of intracellular free cho- stood precisely what is causing that decrease in energy
lesterol in the liver tissue, occasioned by marked up- metabolism.
regulation of ACAT-2 [16, 21] and down-regulation of Dr. Vaziri: As you know, fatty acids are a major fuel
LDL receptor and HDL receptor, plays a major role in for production of energy in the skeletal muscle and myo-
upregulation of HMG-CoA reductase in NS. In addition, cardium and the primary form for long-term storage of
urinary losses of thyroid hormone and gonadal hormones energy in adipose tissue. Chylomicrons and VLDL are
along with their binding proteins can contribute to dys- the primary vehicles for transport of fatty acids (as tri-
regulation of hepatic HMG-CoA reductase expression glycerides) from intestine and liver, respectively. Lipo-
protein lipase catalyzes hydrolysis of triglycerides con-and activity in NS [76]. Finally, hypoalbuminemia per se
tained in VLDL and chylomicrons, and that process leadscontributes to up-regulation of HMG-CoA reductase in
to release and uptake of free fatty acids by myocytesNS. This supposition is based on our recent study demon-
and adipocytes. In addition, VLDL receptor appears tostrating a marked up-regulation of hepatic HMG-CoA
mediate uptake of VLDL, including its triglyceride cargo,reductase protein abundance in rats with hereditary anal-
by myocytes and adipocytes. As I indicated during mybuminemia, in which proteinuria is absent (unpublished
presentation, NS severely down-regulates the LPL anddata). The mechanism by which hypoalbuminemia alters
VLDL receptors, and this down-regulation can nega-expression of HMG-CoA reductase and other proteins
tively affect energy metabolism by limiting availability of
is uncertain. However, it is commonly thought to be fatty acids for energy production and storage in skeletal
mediated by an undefined signal evoked by depressed muscle and adipose tissue.
plasma oncotic pressure in the hepatic sinusoids, in which Dr. Harrington: Second, you mentioned that there
plasma is in direct contact with the hepatocyte. Alterna- was a new inhibitor of ACAT that might have some
tively, the effect of hypoalbuminemia might be due to potential benefit. Can you tell us more about that?
diminished delivery (or increased free forms) of one or Dr. Vaziri: A number of ACAT inhibitors are cur-
more compounds, such as free fatty acids, hormones, rently under investigation as potential lipid-lowering and
minerals, and other materials normally bound to and anti-atherogenic agents. We are currently investigating
the effect of an ACAT inhibitor on lipid metabolism incarried by albumin.
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animal models of NS and chronic renal failure, both proteinuria. In addition, concomitant chronic renal insuf-
ficiency, which down-regulates hepatic LCAT expres-of which are associated with marked up-regulation of
hepatic ACAT-2 expression. We anxiously await the sion, and NS, which results in urinary losses of LCAT,
can lead to severe LCAT deficiency and hence to im-completion of these studies.
Dr. Ronald Perrone (Division of Nephrology, New paired HDL metabolism. With few exceptions, the ad-
vent of severe renal insufficiency is accompanied by aEngland Medical Center, Boston): Would you care to spec-
ulate on the clinical therapies of hyperlipidemia in NS parallel reduction of proteinuria, and the plasma lipid
profile gradually changes from nephrotic dyslipidemiabased on the pathophysiologic abnormalities that you
have identified? to that characteristic of chronic renal failure.
Dr. Bertrand Jaber (Division of Nephrology, NewDr. Vaziri: The most effective step in managing ne-
phrotic dyslipidemia is treating the underlying protein- England Medical Center): You mentioned the possible
role of negative nitrogen balance occasioned by protein-uria. For instance, administration of an angtiotensin-con-
verting-enzyme (ACE) inhibitor, angiotensin II type-1 uria in modifying the liver’s biosynthetic properties.
Could you comment on that and on the role of cytokines(AT-1) receptor blocker, or immunomodulatory agents
as well as dietary protein restriction can help ameliorate in driving the acute-phase reaction in the liver? Finally,
are you aware of any published work identifying the rolenephrotic dyslipidemia by lowering or reversing protein-
uria. However, in many instances, nephrotic-range pro- of inflammatory cytokines in modulating hepatic LCAT
and HMG-CoA reductase activity?teinuria and hence hyperlipidemia persist and necessitate
lipid-lowering therapies, including dietary modifications, Dr. Vaziri: Thank you for raising this important issue.
Heavy proteinuria indeed represents a biologic stressincreased physical activity, and lipid-lowering drugs such
as HMG-CoA reductase inhibitors, bile acid seques- that is frequently accompanied by inflammation and which
leads to increased production of positive-phase reactantstrants, and other agents. I should note that because of
the associated hypoalbuminemia, the biologically active and a relative reduction of negative-phase reactants. To
my knowledge, however, this classification has been pri-free fraction of HMG-CoA reductase inhibitors can be
greater. As such, risk of rhabdomyolysis and hepatic marily applied to plasma proteins, not to the cell-associ-
ated proteins, such as HMG-CoA reductase, which istoxicity can be higher in nephrotic patients as compared
to the general population. Accordingly, liver function an intracellular enzyme. In fact, as I indicated in my
presentation, up-regulation of HMG-CoA reductase intests and muscle enzyme levels should be closely moni-
tored, and caution should be exercised in determining NS appears to be a response to diminished intracellular
free cholesterol, which is occasioned by marked up-regu-appropriate drug dosages in nephrotic patients.
Dr. Madias: Is the nephrotic syndrome associated lation of ACAT-2 and down-regulation of LDL receptor
and HDL receptor. Accordingly, increased abundance ofwith any changes in cholesterol-ester transfer protein?
Dr. Vaziri: Yes. Plasma cholesterol-ester transfer pro- this enzyme in NS reflects a predictable regulatory re-
sponse as opposed to a nonspecific characteristic of acute-tein (CETP) is markedly elevated in patients with NS.
Elevation of CETP, which mediates transfer of choles- phase reactants. On the other hand, LCAT, a liver-derived
plasma protein, can potentially behave as a negative-terol ester from HDL to IDL in exchange for triglycer-
ides, is partly responsible for depressed plasma HDL phase reactant. As I noted earlier, LCAT deficiency in
NS is largely a consequence of its loss in the urine.cholesterol and elevated HDL triglycerides in NS. Be-
cause CETP is absent in rats, we could not study it in Dr. Jaber: What is the effect of HMG-CoA reductase
inhibitors on ACAT activity?our rat models. Absence of CETP in rodents is largely
responsible for a higher plasma HDL cholesterol concen- Dr. Vaziri: I do not have a precise answer to this
important question at this time, but we are currentlytration in these animals and for their natural resistance
against atherogenesis. conducting a series of studies that will provide a defini-
tive answer in the near future. I speculate that the reduc-Dr. Madias: How much do the lipoprotein profile and
the activities of the relevant enzymes change in response tion in cholesterol synthesis caused by HMG-CoA reduc-
tase inhibition down-regulates ACAT by diminishing theto the superimposition of renal insufficiency on the ne-
phrotic state? need for esterification.
Dr. Harrington: Could you comment on the genderDr. Vaziri: Nephrotic syndrome and chronic renal
insufficiency each depress lipoprotein lipase, hepatic tri- differences, if any, in your experimental model of sponta-
neous NS?glyceride lipase, and VLDL receptor. This dysregulation
accounts for impaired clearance of triglyceride-rich lipo- Dr. Vaziri: Renal disease and hyperlipidemia occur
much later in life, are far less severe, and progress muchproteins and their remnants in each of these conditions.
Thus, superimposed renal insufficiency can aggravate the more slowly in female Imai rats. The protective advan-
tage of female gender is lost by oophorectomy in thislipoprotein lipase, hepatic lipase, and VLDL receptor de-
ficiencies in patients and animals with concomitant heavy model pointing to a role for hormonal influences. In
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